azacitidine + tyrosine kinase inhibitor

This combination therapy consists of the hypomethylating agent azacitidine (Vidaza) and a BCR-ABL tyrosine kinase inhibitor (TKI), such as imatinib, dasatinib, or nilotinib. It was investigated in a Phase I/II clinical trial (NCT01460498) led by the M.D. Anderson Cancer Center for the treatment of chronic myeloid leukemia (CML) in patients with minimal residual disease (MRD). Azacitidine, a pyrimidine nucleoside analog, works by inhibiting DNA methyltransferase, leading to DNA hypomethylation and the potential reactivation of tumor suppressor genes. The TKI component targets the constitutive tyrosine kinase activity of the BCR-ABL fusion protein, which is the hallmark of CML. The goal of this combination is to eliminate residual leukemic stem cells that may be resistant to TKI monotherapy by modifying the epigenetic landscape of the disease.

Other names

azacitidine + TKIVidaza + tyrosine kinase inhibitorazacitidine + imatinibazacitidine + dasatinibazacitidine + nilotinib